Skip to main content

Table 1 The characteristics of the eleven included studies

From: Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systemic review and meta-analysis

First author/year

Location

Design

AKI criteria

Population

Sample size

Furosemide dose

Urine output cutoff point

Outcome of interest

Enrolled patients AKI stage

High plasma NGAL

Exclusion of chronic kidney disease

Chawla, 2013 [8]

USA

PC+RC

AKIN

Mixed

77

1 mg/kg (furosemide naïve) or 1.5 mg/kg (furosemide non-naive)

200 ml/2 h

AKIN stage 3

AKIN stage 1–2

Yes

Yes (eGFR < 30)

Elsaegh, 2018 [14]

Egypt

PC

KDIGO

Sepsis

60

KDIGO stage progression (included RRT)

Normal renal function and any stage of AKI

No

Yes

Lumlertgul, 2018 [15]

Thailand

PC

KDIGO

Mixed

162

RRT

Any stage of AKI

Yes

Yes (baseline Cr > 2)

Martínez, 2016 [16]

Mexico

PC

KDGO

NA

20

KDIGO stage-3 and RRT

KDIGO stage 1–2

No

Yes (eGFR < 30)

Matsuura, 2018 [17]

Japan

RC

KDIGO

Mixed

51

NA

3.9 ml/2 h for per milligram furosemide

KDIGO stage 3 and RRT

KDIGO stage 1–2 or high NGAL with normal renal function

Yes

No

Pérez-Cruz, 2017 [18]

Mexico

PC

AKIN

Medical

35

1 mg/kg (furosemide naive) or 1.5 mg/kg (furosemide non-naive)

200 ml/2 h

AKIN-3 and RRT

AKIN stage 1–2

No

No

Rewa, 2019 [19]

USA and Canada

PC

AKIN

Mixed

92

AKIN stage 3

AKIN stage 1–2

No

Yes (eGFR < 30)

Saber, 2018 [20]

Egypt

PC

AKIN

NA

40

325 ml/6 h

AKIN stage 3 (included RRT)

AKIN stage 1–2

No

Yes (eGFR < 30)

Sakhuja, 2019 [21]

USA

RC

AKIN

NA

687

≥ 1 mg/kg

600 ml/6 h

RRT

AKIN stage 3

No

No

Vairakkani, 2019 [22]

India

NA

KDIGO

NA

80

1 mg/kg (furosemide naive) or 1.5 mg/kg (furosemide non-naive)

325 ml/2 h

KDIGO stage 3

KDIGO stage 1–2

No

Yes (eGFR < 30)

Venugopal, 2019 [23]

India

PC

AKIN

NA

62

200 ml/2 h

AKIN-3 and RRT

AKIN stage 1–2

No

No

  1. Abbreviation: AKI acute kidney injury, AKIN Acute Kidney Injury Network, Cr creatinine, eGFR estimated glomerular filtration rate, KDIGO Kidney Disease Global outcomes, NA not applicable, PC prospective cohort, RC retrospective cohort, RRT renal replacement therapy